troglitazone has been researched along with Cardiac Hypertrophy in 5 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo." | 7.71 | Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002) |
| "Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo." | 3.71 | Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002) |
| " In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice." | 3.71 | Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. ( Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Zhang, H | 1 |
| Shao, Z | 1 |
| O'Hara, KA | 1 |
| Kopilas, MA | 1 |
| Yu, L | 1 |
| Netticadan, T | 1 |
| Anderson, HD | 1 |
| Sakai, S | 1 |
| Miyauchi, T | 1 |
| Irukayama-Tomobe, Y | 1 |
| Ogata, T | 1 |
| Goto, K | 1 |
| Yamaguchi, I | 1 |
| Yamamoto, K | 1 |
| Ohki, R | 1 |
| Lee, RT | 1 |
| Ikeda, U | 1 |
| Shimada, K | 1 |
| Asakawa, M | 1 |
| Takano, H | 1 |
| Nagai, T | 1 |
| Uozumi, H | 1 |
| Hasegawa, H | 1 |
| Kubota, N | 1 |
| Saito, T | 1 |
| Masuda, Y | 1 |
| Kadowaki, T | 1 |
| Komuro, I | 1 |
| Makino, N | 1 |
| Hirayama, H | 1 |
| Yonemochi, H | 1 |
| Yano, K | 1 |
| Abe, N | 1 |
1 trial available for troglitazone and Cardiac Hypertrophy
| Article | Year |
|---|---|
Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.
Topics: Cardiomegaly; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Humans; | 2001 |
4 other studies available for troglitazone and Cardiac Hypertrophy
| Article | Year |
|---|---|
Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta.
Topics: Age Factors; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Chromans; Diacylglycerol Kina | 2011 |
Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.
Topics: Analysis of Variance; Animals; Cardiomegaly; Chromans; Endothelin-1; Endothelins; Male; Natriuretic | 2002 |
Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes.
Topics: Angiotensin II; Animals; Animals, Newborn; Biological Transport; Cardiomegaly; Cells, Cultured; Chro | 2001 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Ce | 2002 |